Opinion
Video
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Assessing Lesion Types With MS Biomarkers
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss how use of biomarkers has affected understanding and assessment of lesion types.
In this part of the conversation, Mark Freedman, MD, MSc, discusses the data showing that gadolinium-enhancing lesions are often the ones that heal and exhibit remyelination. He challenges the assumption that every enhancing lesion is necessarily bad and highlights the complexity of interpreting such lesions.
Tanuja Chitnis, MD, acknowledges the potential reparative potential of some cells moving into the brain with gadolinium-enhancing lesions. However, she emphasizes the general goal of reducing gadolinium-enhancing lesions, and the variability in axonal damage and lesion types between individuals. Experts further underscore the limitations of markers like NFL and the potential inaccuracies associated with individual cases.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
